A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine

NCT07703475 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

80

Enrollment

NIH

Sponsor class

Conditions

COVID -19

Interventions

BIOLOGICAL: RVX-sCPD9

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)